Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis

– Top-Line Results Anticipated in March 2026 –

NEWTON, Mass., Sept. 10, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has completed enrollment in the Phase 3 SENTRY trial, which is evaluating selinexor in combination with ruxolitinib in JAKi-naïve myelofibrosis patients.

Read more at prnewswire.com